Role of HIV-1 envelope glycoproteins conformation and accessory proteins on ADCC responses

Current HIV Research

Volumn 14, Issue 1, 2016, Pages 9-23

  Veillette, Maxime ^a,b   Richard, Jonathan ^a,b   Pazgier, Marzena ^c   Lewis, George K ^c   Parsons, Matthew S ^d   Finzi, Andrés ^a,b,e  

^a CENTRE HOSPITALIER DE L UNIVERSITÉ DE MONTRÉAL   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^d UNIVERSITY OF MELBOURNE   (Australia)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

ADCC; BST 2; CD4; Envelope glycoproteins; Gp120; Gp41; HIV 1; Nef; Non neutralizing antibodies; Vpu

Indexed keywords

CD4 ANTIGEN; EPITOPE; GLYCOPROTEIN GP 120; GLYCOPROTEIN GP 41; GRANZYME B; IMMUNOGLOBULIN F(AB) FRAGMENT; LYSOSOME ASSOCIATED MEMBRANE PROTEIN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 1; NEF PROTEIN; NEUTRALIZING ANTIBODY; VIRUS FUSION PROTEIN; VIRUS GLYCOPROTEIN; VIRUS VACCINE; VPU PROTEIN; GRANZYME; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; PROTEIN BINDING;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ANTIBODY DETECTION; ANTIGEN ANTIBODY REACTION; CD4+ T LYMPHOCYTE; CHROMIUM RELEASE ASSAY; CYTOTOXIC T LYMPHOCYTE; DOWN REGULATION; ELIMINATION REACTION; GENE INACTIVATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; LEUKOCYTE MIGRATION; LUCIFERASE ASSAY; MUTAGENESIS; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; PROTEIN PROTEIN INTERACTION; REVIEW; SIMIAN ACQUIRED IMMUNODEFICIENCY SYNDROME; SURFACE PLASMON RESONANCE; VIRUS ENTRY; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; CELL COMMUNICATION; CHEMISTRY; FLUOROMETRY; HIV INFECTIONS; IMMUNOLOGY; LYMPHOCYTE ACTIVATION; METABOLISM; NATURAL KILLER CELL; PROTEIN CONFORMATION; TRANSMISSION;

AIDS VACCINES; ANTIBODY-DEPENDENT CELL CYTOTOXICITY; ANTIGENS, CD4; CELL COMMUNICATION; EPITOPES; FLUOROMETRY; GRANZYMES; HIV ANTIBODIES; HIV ENVELOPE PROTEIN GP120; HIV INFECTIONS; HIV-1; HUMANS; KILLER CELLS, NATURAL; LYMPHOCYTE ACTIVATION; PROTEIN BINDING; PROTEIN CONFORMATION;

EID: 84958062076     PISSN: 1570162X     EISSN: 18734251     Source Type: Journal    
DOI: 10.2174/1570162X13666150827093449     Document Type: Review

References (150)

1. Rerks-Ngarm S, Pitisuttithum P, Nitayaphan S, et al. Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. New Engl J Med 2009; 361(23): 2209-20.
2. Haynes BF, Gilbert PB, McElrath MJ, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. New Engl J Med 2012; 366(14): 1275-86.
3. Bonsignori M, Pollara J, Moody MA, et al. Antibody-Dependent Cellular Cytotoxicity-Mediating Antibodies from an HIV-1 Vaccine Efficacy Trial Target Multiple Epitopes and Preferentially Use the VH1 Gene Family. J Virol 2012; 86(21): 11521-32.
4. Kohl S. Role of antibody-dependent cellular cytotoxicity in defense against herpes simplex virus infections. Rev Infect Dis 1991; 13(1): 108-14.
5. Beltran D, Lopez-Verges S. NK Cells during Dengue Disease and Their Recognition of Dengue Virus-Infected cells. Front Immunol 2014; 5: 192.
6. Jegaskanda S, Weinfurter JT, Friedrich TC, Kent SJ. Antibodydependent cellular cytotoxicity is associated with control of pandemic H1N1 influenza virus infection of macaques. J Virol 2013; 87(10): 5512-22.
7. Banks ND, Kinsey N, Clements J, Hildreth JE. Sustained antibodydependent cell-mediated cytotoxicity (ADCC) in SIV-infected macaques correlates with delayed progression to AIDS. Aids Res Hum Retrov 2002; 18(16): 1197-205.
8. Sun Y, Asmal M, Lane S, et al. Antibody-dependent cell-mediated cytotoxicity in simian immunodeficiency virus-infected rhesus monkeys. J Virol 2011; 85(14): 6906-12.
9. Alpert MD, Harvey JD, Lauer WA, et al. ADCC develops over time during persistent infection with live-attenuated SIV and is associated with complete protection against SIV(mac)251 challenge. PLoS Pathogens 2012; 8(8) : e1002890.
10. Baum LL, Cassutt KJ, Knigge K, et al. HIV-1 gp120-specific antibody-dependent cell-mediated cytotoxicity correlates with rate of disease progression. J Immunol 1996; 157(5): 2168-73.
11. Forthal DN, Landucci G, Haubrich R, et al. Antibody-dependent cellular cytotoxicity independently predicts survival in severely immunocompromised human immunodeficiency virus-infected patients. J Infect Dis 1999; 180(4): 1338-41.
12. Ljunggren K, Moschese V, Broliden PA, et al. Antibodies mediating cellular cytotoxicity and neutralization correlate with a better clinical stage in children born to human immunodeficiency virus-infected mothers. J Infect Dis 1990; 161(2): 198-202.
13. Chung AW, Navis M, Isitman G, et al. Activation of NK cells by ADCC antibodies and HIV disease progression. J Acquir Immune Defic Syndr 2011; 58(2): 127-31.
14. Mabuka J, Nduati R, Odem-Davis K, Peterson D, Overbaugh J. HIV-specific antibodies capable of ADCC are common in breastmilk and are associated with reduced risk of transmission in women with high viral loads. PLoS Pathogens 2012; 8(6): e1002739.
15. Milligan C, Richardson BA, John-Stewart G, Nduati R, Overbaugh J. Passively acquired antibody-dependent cellular cytotoxicity (ADCC) activity in HIV-infected infants is associated with reduced mortality. Cell Host Microbe 2015; 17(4): 500-6.
16. Milligan C, Overbaugh J. The role of cell-associated virus in mother-to-child HIV transmission. J Infect Dis 2014; 210 Suppl 3: S631-40.
17. Johansson SE, Rollman E, Chung AW, et al. NK cell function and antibodies mediating ADCC in HIV-1-infected viremic and controller patients. Viral Immunol 2011: 24(5): 359-68.
18. Smalls-Mantey A, Doria-Rose N, Klein R, et al. Antibodydependent cellular cytotoxicity against primary HIV-infected CD4+ T cells is directly associated with the magnitude of surface IgG binding. J Virol 2012; 86(16): 8672-80.
19. Dalgleish A, Sinclair A, Steel M, et al. Failure of ADCC to predict HIV-associated disease progression or outcome in a haemophiliac cohort. Clin Exp Immunol 1990; 81(1): 5-10.
20. Koup RA, Sullivan JL, Levine PH, et al. Antigenic specificity of antibody-dependent cell-mediated cytotoxicity directed against human immunodeficiency virus in antibody-positive sera. J Virol 1989; 63(2): 584-90.
21. Dugast AS, Chan Y, Hoffner M, et al. Lack of protection following passive transfer of polyclonal highly functional low-dose nonneutralizing antibodies. PloS One 2014; 9(5): e97229.
22. Nakane T, Nomura T, Shi S, et al. Limited impact of passive nonneutralizing antibody immunization in acute SIV infection on viremia control in rhesus macaques. PloS One 2013; 8(9): e73453.
23. Moog C, Dereuddre-Bosquet N, Teillaud JL, et al. Protective effect of vaginal application of neutralizing and nonneutralizing inhibitory antibodies against vaginal SHIV challenge in macaques. Mucosal Immunol 2014; 7(1): 46-56.
24. Santra S, Tomaras GD, Warrier R, et al. Human Non-neutralizing HIV-1 Envelope Monoclonal Antibodies Limit the Number of Founder Viruses during SHIV Mucosal Infection in Rhesus Macaques. PLoS Pathogens 2015; 11(8): e1005042.
25. Checkley MA, Luttge BG, Freed EO. HIV-1 envelope glycoprotein biosynthesis, trafficking, and incorporation. J Mol Biol 2011; 410(4): 582-608.
26. Batraville LA, Richard J, Veillette M, et al. Short Communication: Anti-HIV-1 Envelope Immunoglobulin Gs in Blood and Cervicovaginal Samples of Beninese Commercial Sex Workers. Aids Res Hum Retrov 2014; 30(11): 1145-9.
27. Richard J, Veillette M, Batraville LA, et al. Flow cytometry-based assay to study HIV-1 gp120 specific antibody-dependent cellular cytotoxicity responses. J Virol Methods 2014; 208C: 107-14.
28. Veillette M, Coutu M, Richard J, et al. The HIV-1 gp120 CD4-bound conformation is preferentially targeted by antibodydependent cellular cytotoxicity-mediating antibodies in sera from HIV-1-infected individuals. J Virol 2015; 89(1): 545-51.
29. Veillette M, Coutu M, Richard J, et al. Conformational Evaluation of HIV-1 Trimeric Envelope Glycoproteins Using a Cell-based ELISA Assay. Journal of visualized experiments: JoVE 2014 (91).
30. Veillette M, Desormeaux A, Medjahed H, et al. Interaction with Cellular CD4 Exposes HIV-1 Envelope Epitopes Targeted by Antibody-Dependent Cell-Mediated Cytotoxicity. J Virol 2014; 88(5): 2633-44.
31. Alvarez RA, Hamlin RE, Monroe A, et al. HIV-1 Vpu antagonism of tetherin inhibits antibody-dependent cellular cytotoxic responses by natural killer cells. J Virol 2014; doi: 10.1128/JVI.00449-14.
32. Arias JF, Heyer LN, von Bredow B, et al. Tetherin antagonism by Vpu protects HIV-infected cells from antibody-dependent cellmediated cytotoxicity. Proc Natl Acad Sci USA 2014; doi: 10.1073/pnas.1321507111.
33. Acharya P, Tolbert WD, Gohain N, et al. Structural definition of an antibody-dependent cellular cytotoxicity response implicated in reduced risk for HIV-1 infection. J Virol 2014; 88(21): 12895-906.
34. Decker JM, Bibollet-Ruche F, Wei X, et al. Antigenic conservation and immunogenicity of the HIV coreceptor binding site. The J Experiment Med 2005; 201(9): 1407-19.
35. Guan Y, Pazgier M, Sajadi MM, et al. Diverse specificity and effector function among human antibodies to HIV-1 envelope glycoprotein epitopes exposed by CD4 binding. Proc Natl Acad Sci USA 2013; 110(1): E69-78.
36. Ferrari G, Pollara J, Kozink D, et al. An HIV-1 gp120 envelope human monoclonal antibody that recognizes a C1 conformational epitope mediates potent antibody-dependent cellular cytotoxicity (ADCC) activity and defines a common ADCC epitope in human HIV-1 serum. J Virol 2011; 85(14): 7029-36.
37. Finzi A, Xiang SH, Pacheco B, et al. Topological layers in the HIV-1 gp120 inner domain regulate gp41 interaction and CD4-triggered conformational transitions. Mol Cell 2010; 37(5): 656-67.
38. von Bredow B, Arias JF, Heyer LN, et al. Envelope glycoprotein internalization protects human and simian immunodeficiency virus infected cells from antibody-dependent cell-mediated cytotoxicity. J Virol 2015: Epub 2015 Aug 12.
39. Dey B, Pancera M, Svehla K, et al. Characterization of human immunodeficiency virus type 1 monomeric and trimeric gp120 glycoproteins stabilized in the CD4-bound state: antigenicity, biophysics, and immunogenicity. J Virol 2007; 81(11): 5579-93.
40. Veillette M, Richard J, Finzi A. Uncovering HIV-1-infected cells. Oncotarget 2015; 6(26): 21791-2.
41. Helseth E, Olshevsky U, Furman C, Sodroski J. Human immunodeficiency virus type 1 gp120 envelope glycoprotein regions important for association with the gp41 transmembrane glycoprotein. J Virol 1991; 65(4): 2119-23.
42. Yang X, Mahony E, Holm GH, Kassa A, Sodroski J. Role of the gp120 inner domain beta-sandwich in the interaction between the human immunodeficiency virus envelope glycoprotein subunits. Virology 2003; 313(1): 117-25.
43. Allan JS, Coligan JE, Barin F, et al. Major glycoprotein antigens that induce antibodies in AIDS patients are encoded by HTLV-III. Science 1985; 228(4703): 1091-4.
44. Robey WG, Safai B, Oroszlan S, et al. Characterization of envelope and core structural gene products of HTLV-III with sera from AIDS patients. Science 1985; 228(4699): 593-5.
45. Dalgleish AG, Beverley PC, Clapham PR, et al. The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus. Nature 1984; 312(5996): 763-7.
46. Klatzmann D, Champagne E, Chamaret S, et al. T-lymphocyte T4 molecule behaves as the receptor for human retrovirus LAV. Nature 1984; 312(5996): 767-8.
47. Alkhatib G, Combadiere C, Broder CC, et al. CC CKR5: a RANTES, MIP-1alpha, MIP-1beta receptor as a fusion cofactor for macrophage-tropic HIV-1. Science 1996; 272(5270): 1955-8.
48. Choe H, Farzan M, Sun Y, et al. The beta-chemokine receptors CCR3 and CCR5 facilitate infection by primary HIV-1 isolates. Cell 1996; 85(7): 1135-48.
49. Deng H, Liu R, Ellmeier W, et al. Identification of a major coreceptor for primary isolates of HIV-1. Nature 1996; 381(6584): 661-6.
50. Doranz BJ, Rucker J, Yi Y, et al. A dual-tropic primary HIV-1 isolate that uses fusin and the beta-chemokine receptors CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 1996; 85(7): 1149-58.
51. Dragic T, Litwin V, Allaway GP, et al. HIV-1 entry into CD4+ cells is mediated by the chemokine receptor CC-CKR-5. Nature 1996; 381(6584): 667-73.
52. Feng Y, Broder CC, Kennedy PE, Berger EA. HIV-1 entry cofactor: functional cDNA cloning of a seven-transmembrane, G protein-coupled receptor. Science 1996; 272(5263): 872-7.
53. Wu L, Gerard NP, Wyatt R, et al. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature 1996; 384(6605): 179-83.
54. Trkola A, Dragic T, Arthos J, et al. CD4-dependent, antibodysensitive interactions between HIV-1 and its co-receptor CCR-5. Nature 1996; 384(6605): 184-7.
55. Furuta RA, Wild CT, Weng Y, Weiss CD. Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol 1998; 5(4): 276-9.
56. He Y, Vassell R, Zaitseva M, et al. Peptides trap the human immunodeficiency virus type 1 envelope glycoprotein fusion intermediate at two sites. J Virol 2003; 77(3): 1666-71.
57. Koshiba T, Chan DC. The prefusogenic intermediate of HIV-1 gp41 contains exposed C-peptide regions. J Biol Chem 2003; 278(9): 7573-9.
58. Si Z, Madani N, Cox JM, et al. Small-molecule inhibitors of HIV-1 entry block receptor-induced conformational changes in the viral envelope glycoproteins. Proc Natl Acad Sci USA 2004; 101(14): 5036-41.
59. Chan DC, Fass D, Berger JM, Kim PS. Core structure of gp41 from the HIV envelope glycoprotein. Cell. 1997; 89(2): 263-73.
60. Lu M, Blacklow SC, Kim PS. A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol 1995; 2(12): 1075-82.
61. Weissenhorn W, Dessen A, Harrison SC, Skehel JJ, Wiley DC. Atomic structure of the ectodomain from HIV-1 gp41. Nature. 1997; 387(6631): 426-30.
62. Liu J, Bartesaghi A, Borgnia MJ, Sapiro G, Subramaniam S. Molecular architecture of native HIV-1 gp120 trimers. Nature 2008; 455(7209): 109-13.
63. Tran EE, Borgnia MJ, Kuybeda O, et al. Structural mechanism of trimeric HIV-1 envelope glycoprotein activation. PLoS Pathogens 2012; 8(7): e1002797.
64. Madani N, Princiotto AM, Schon A, et al. CD4-mimetic small molecules sensitize human immunodeficiency virus to vaccineelicited antibodies. J Virol 2014; 88(12): 6542-55.
65. Desormeaux A, Coutu M, Medjahed H, et al. The highly conserved layer-3 component of the HIV-1 gp120 inner domain is critical for CD4-required conformational transitions. J Virol 2013; 87(5): 2549-62.
66. Kassa A, Madani N, Schon A, et al. Transitions to and from the CD4-bound conformation are modulated by a single-residue change in the human immunodeficiency virus type 1 gp120 inner domain. J Virol 2009; 83(17): 8364-78.
67. Kwon YD, Finzi A, Wu X, et al. Unliganded HIV-1 gp120 core structures assume the CD4-bound conformation with regulation by quaternary interactions and variable loops. Proc Natl Acad Sci USA 2012; 109(15): 5663-8.
68. Liu L, Cimbro R, Lusso P, Berger EA. Intraprotomer masking of third variable loop (V3) epitopes by the first and second variable loops (V1V2) within the native HIV-1 envelope glycoprotein trimer. Proc Natl Acad Sci USA 2011; 108(50): 20148-53.
69. Rusert P, Krarup A, Magnus C, et al. Interaction of the gp120 V1V2 loop with a neighboring gp120 unit shields the HIV envelope trimer against cross-neutralizing antibodies. J Experiment Med 2011; 208(7): 1419-33.
70. Medjahed H, Pacheco B, Desormeaux A, Sodroski J, Finzi A. The HIV-1 gp120 major variable regions modulate cold inactivation. J Virol 2013; 87(7): 4103-11.
71. Zhuang K, Finzi A, Toma J, et al. Identification of interdependent variables that influence coreceptor switch in R5 SHIV(SF162P3N)-infected macaques. Retrovirology 2012; 9: 106.
72. Zhuang K, Finzi A, Tasca S, et al. Adoption of an "open" envelope conformation facilitating CD4 binding and structural remodeling precedes coreceptor switch in R5 SHIV-infected macaques. PloS One 2011; 6(7): e21350.
73. Wyatt R, Moore J, Accola M, et al. Involvement of the V1/V2 variable loop structure in the exposure of human immunodeficiency virus type 1 gp120 epitopes induced by receptor binding. J Virol 1995; 69(9): 5723-33.
74. Moore JP, Trkola A, Korber B, et al. A human monoclonal antibody to a complex epitope in the V3 region of gp120 of human immunodeficiency virus type 1 has broad reactivity within and outside clade B. J Virol 1995; 69(1): 122-30.
75. Pancera M, Majeed S, Ban YE, et al. Structure of HIV-1 gp120 with gp41-interactive region reveals layered envelope architecture and basis of conformational mobility. Proc Natl Acad Sci USA 2010; 107(3): 1166-71.
76. Tomaras GD, Ferrari G, Shen X, et al. Vaccine-induced plasma IgA specific for the C1 region of the HIV-1 envelope blocks binding and effector function of IgG. Proc Natl Acad Sci USA 2013; 110(22): 9019-24.
77. Moore JP, Willey RL, Lewis GK, Robinson J, Sodroski J. Immunological evidence for interactions between the first, second, and fifth conserved domains of the gp120 surface glycoprotein of human immunodeficiency virus type 1. J Virol 1994; 68(11): 6836-47.
78. Gohain N, Tolbert WD, Acharya P, et al. Cocrystal Structures of Antibody N60-i3 and Antibody JR4 in Complex with gp120 Define More Cluster A Epitopes Involved in Effective Antibody-Dependent Effector Function against HIV-1. J Virol 2015; 89(17): 8840-54.
79. Ray K, Mengistu M, Yu L, et al. Antigenic properties of the HIV envelope on virions in solution. J Virol 2014; 88(3): 1795-808.
80. Mengistu M, Ray K, Lewis GK, DeVico AL. Antigenic properties of the human immunodeficiency virus envelope glycoprotein gp120 on virions bound to target cells. PLoS Pathogens 2015; 11(3): e1004772.
81. Schwartz O, Dautry-Varsat A, Goud B, et al. Human immunodeficiency virus type 1 Nef induces accumulation of CD4 in early endosomes. J Virol 1995; 69(1): 528-33.
82. Willey RL, Maldarelli F, Martin MA, Strebel K. Human immunodeficiency virus type 1 Vpu protein induces rapid degradation of CD4. J Virol 1992; 66(12): 7193-200.
83. Neil SJ, Zang T, Bieniasz PD. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 2008; 451(7177): 425-30.
84. Van Damme N, Goff D, Katsura C, et al. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein. Cell Host Microbe 2008; 3(4): 245-52.
85. Mwimanzi P, Markle TJ, Martin E, et al. Attenuation of multiple Nef functions in HIV-1 elite controllers. Retrovirology 2013; 10: 1.
86. Kuang XT, Li X, Anmole G, et al. Impaired Nef function is associated with early control of HIV-1 viremia. J Virol 2014; 88(17): 10200-13.
87. Arnold P, Himmels P, Weiss S, et al. Antigenic and 3D structural characterization of soluble X4 and hybrid X4-R5 HIV-1 Env trimers. Retrovirology 2014; 11: 42.
88. O'Brien WA, Mao SH, Cao Y, Moore JP. Macrophage-tropic and T-cell line-adapted chimeric strains of human immunodeficiency virus type 1 differ in their susceptibilities to neutralization by soluble CD4 at different temperatures. J Virol 1994; 68(8): 5264-9.
89. Haim H, Strack B, Kassa A, et al. Contribution of intrinsic reactivity of the HIV-1 envelope glycoproteins to CD4-independent infection and global inhibitor sensitivity. PLoS Pathogens 2011; 7(6): e1002101.
90. Haim H, Salas I, McGee K, et al. Modeling virus-and antibodyspecific factors to predict human immunodeficiency virus neutralization efficiency. Cell Host Microbe 2013; 14(5): 547-58.
91. Zhao Q, Ma L, Jiang S, et al. Identification of N-phenyl-N’-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4. Virology 2005; 339(2): 213-25.
92. LaLonde JM, Kwon YD, Jones DM, et al. Structure-based design, synthesis, and characterization of dual hotspot small-molecule HIV-1 entry inhibitors. J Med Chem 2012; 55(9): 4382-96.
93. Lalonde JM, Le-Khac M, Jones DM, et al. Structure-Based Design and Synthesis of an HIV-1 Entry Inhibitor Exploiting X-Ray and Thermodynamic Characterization. ACS Med Chem Letters 2013; 4(3): 338-43.
94. Madani N, Schon A, Princiotto AM, et al. Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120. Structure 2008; 16(11): 1689-701.
95. Kwong PD, Wyatt R, Robinson J, et al. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature 1998; 393(6686): 648-59.
96. Schon A, Madani N, Klein JC, et al. Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120. Biochem 2006; 45(36): 10973-80.
97. Martin L, Stricher F, Misse D, et al. Rational design of a CD4 mimic that inhibits HIV-1 entry and exposes cryptic neutralization epitopes. Nature Biotech 2003; 21(1): 71-6.
98. Van Herrewege Y, Morellato L, Descours A, et al. CD4 mimetic miniproteins: potent anti-HIV compounds with promising activity as microbicides. J Antimicrob Chemother 2008; 61(4): 818-26.
99. Acharya P, Luongo TS, Louder MK, et al. Structural basis for highly effective HIV-1 neutralization by CD4-mimetic miniproteins revealed by 1.5 A cocrystal structure of gp120 and M48U1. Structure 2013; 21(6): 1018-29.
100. Richard J, Veillette M, Brassard N, et al. CD4 mimetics sensitize HIV-1-infected cells to ADCC. Proc Natl Acad Sci USA 2015; 112(20): E2687-94.
101. Bouchet J, Basmaciogullari SE, Chrobak P, et al. Inhibition of the Nef regulatory protein of HIV-1 by a single-domain antibody. Blood 2011; 117(13): 3559-68.
102. Tyler DS, Stanley SD, Nastala CA, et al. Alterations in antibodydependent cellular cytotoxicity during the course of HIV-1 infection. Humoral and cellular defects. J Immunol 1990; 144(9): 3375-84.
103. Ahmad A, Morisset R, Thomas R, Menezes J. Evidence for a defect of antibody-dependent cellular cytotoxic (ADCC) effector function and anti-HIV gp120/41-specific ADCC-mediating antibody titres in HIV-infected individuals. J Acquir Immune Defic Syndr 1994; 7(5): 428-37.
104. Nelson DL, Kurman CC, Serbousek DE. 51Cr release assay of antibody-dependent cell-mediated cytotoxicity (ADCC). Current protocols in immunology/edited by John E Coligan [et al]. 2001; Chapter 7: Unit 7 27.
105. Howell DN, Andreotti PE, Dawson JR, Cresswell P. Natural killing target antigens as inducers of interferon: studies with an immunoselected, natural killing-resistant human T lymphoblastoid cell line. J Immunol 1985; 134(2): 971-6.
106. Stratov I, Chung A, Kent SJ. Robust NK cell-mediated human immunodeficiency virus (HIV)-specific antibody-dependent responses in HIV-infected subjects. J Virol 2008; 82(11): 5450-9.
107. Chung AW, Rollman E, Center RJ, Kent SJ, Stratov I. Rapid degranulation of NK cells following activation by HIV-specific antibodies. J Immunol 2009; 182(2): 1202-10.
108. Alter G, Malenfant JM, Altfeld M. CD107a as a functional marker for the identification of natural killer cell activity. J Immunol Methods 2004; 294(1-2): 15-22.
109. Chung AW, Isitman G, Navis M, et al. Immune escape from HIVspecific antibody-dependent cellular cytotoxicity (ADCC) pressure. Proc Natl Acad Sci USA 2011; 108(18): 7505-10.
110. Isitman G, Chung AW, Navis M, Kent SJ, Stratov I. Pol as a target for antibody dependent cellular cytotoxicity responses in HIV-1 infection. Virology 2011; 412(1): 110-6.
111. Wren LH, Chung AW, Isitman G, et al. Specific antibodydependent cellular cytotoxicity responses associated with slow progression of HIV infection. Immunology 2013; 138(2): 116-23.
112. Gooneratne SL, Richard J, Lee WS, et al. Slaying the Trojan horse: natural killer cells exhibit robust anti-HIV-1 antibody-dependent activation and cytolysis against allogeneic T cells. J Virol 2015; 89(1): 97-109.
113. Pollara J, Hart L, Brewer F, et al. High-throughput quantitative analysis of HIV-1 and SIV-specific ADCC-mediating antibody responses. Cytometry Part A: J Int Soc Anal Cytol 2011; 79(8): 603-12.
114. Sheehy ME, McDermott AB, Furlan SN, Klenerman P, Nixon DF. A novel technique for the fluorometric assessment of T lymphocyte antigen specific lysis. J Immunol Methods 2001; 249(1-2): 99-110.
115. Gomez-Roman VR, Florese RH, Patterson LJ, et al. A simplified method for the rapid fluorometric assessment of antibodydependent cell-mediated cytotoxicity. J Immunol Methods 2006; 308(1-2): 53-67.
116. Gomez-Roman VR, Patterson LJ, Venzon D, et al. Vaccine-elicited antibodies mediate antibody-dependent cellular cytotoxicity correlated with significantly reduced acute viremia in rhesus macaques challenged with SIVmac251. J Immunol 2005; 174(4): 2185-9.
117. Patterson LJ, Daltabuit-Test M, Xiao P, et al. Rapid SIV Envspecific mucosal and serum antibody induction augments cellular immunity in protecting immunized, elite-controller macaques against high dose heterologous SIV challenge. Virology 2011; 411(1): 87-102.
118. Xiao P, Zhao J, Patterson LJ, et al. Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques. J Virol 2010; 84(14): 7161-73.
119. Fouts TR, Bagley K, Prado IJ, et al. Balance of cellular and humoral immunity determines the level of protection by HIV vaccines in rhesus macaque models of HIV infection. Proc Natl Acad Sci USA 2015; 112(9): E992-9.
120. Kramski M, Schorcht A, Johnston AP, et al. Role of monocytes in mediating HIV-specific antibody-dependent cellular cytotoxicity. J Immunol Methods 2012; 384(1-2): 51-61.
121. Pham TN, Lukhele S, Hajjar F, Routy JP, Cohen EA. HIV Nef and Vpu protect HIV-infected CD4+ T cells from antibody-mediated cell lysis through down-modulation of CD4 and BST2. Retrovirol 2014; 11: 15.
122. Anderson DJ, Politch JA, Nadolski AM, et al. Targeting Trojan Horse leukocytes for HIV prevention. AIDS 2010; 24(2): 163-87.
123. Anderson DJ, Yunis EJ. “Trojan Horse” leukocytes in AIDS. New Eng J Med 1983; 309(16): 984-5.
124. Barreto-de-Souza V, Arakelyan A, Margolis L, Vanpouille C. HIV-1 vaginal transmission: cell-free or cell-associated virus? Am J Reprod Immunol 2014; 71(6): 589-99.
125. Levy JA. The transmission of AIDS: the case of the infected cell. JAMA 1988; 259(20): 3037-8.
126. Ndirangu J, Viljoen J, Bland RM, et al. Cell-free (RNA) and cellassociated (DNA) HIV-1 and postnatal transmission through breastfeeding. PloS One 2012; 7(12): e51493.
127. Russell RR, Bowmer MI, Nguyen C, Grant MD. HIV-1 DNA burden in peripheral blood CD4+ cells influences disease progression, antiretroviral efficacy, and CD4+ T-cell restoration. Viral Immunol 2001; 14(4): 379-89.
128. Zara F, Nappi RE, Brerra R, et al. Markers of local immunity in cervico-vaginal secretions of HIV infected women: implications for HIV shedding. Sex Transm Infect 2004; 80(2): 108-12.
129. Zhu T, Wang N, Carr A, et al. Genetic characterization of human immunodeficiency virus type 1 in blood and genital secretions: evidence for viral compartmentalization and selection during sexual transmission. J Virol 1996; 70(5): 3098-107.
130. Di Fabio S, Giannini G, Lapenta C, et al. Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001; 15(17): 2231-8.
131. Salle B, Brochard P, Bourry O, et al. Infection of macaques after vaginal exposure to cell-associated simian immunodeficiency virus. J Infect Dis 2010; 202(3): 337-44.
132. Kingsley C, Peters B, Babaahmady K, et al. Heterosexual and homosexual partners practising unprotected sex may develop allogeneic immunity and to a lesser extent tolerance. PloS One 2009; 4(11): e7938.
133. Bishop SA, Stokes CR, Gruffydd-Jones TJ, Whiting CV, Harbour DA. Vaginal and rectal infection of cats with feline immunodeficiency virus. Vet Microbiol 1996; 51(3-4): 217-27.
134. Heeney JL, van Els C, de Vries P, et al. Major histocompatibility complex class I-associated vaccine protection from simian immunodeficiency virus-infected peripheral blood cells. J Experiment Med 1994; 180(2): 769-74.
135. Kolodkin-Gal D, Hulot SL, Korioth-Schmitz B, et al. Efficiency of cell-free and cell-associated virus in mucosal transmission of human immunodeficiency virus type 1 and simian immunodeficiency virus. J Virol 2013; 87(24): 13589-97.
136. Sodora DL, Gettie A, Miller CJ, Marx PA. Vaginal transmission of SIV: assessing infectivity and hormonal influences in macaques inoculated with cell-free and cell-associated viral stocks. AIDS Res Hum Retrov 1998; 14 Suppl 1: S119-23.
137. Weiler AM, Li Q, Duan L, et al. Genital ulcers facilitate rapid viral entry and dissemination following intravaginal inoculation with cell-associated simian immunodeficiency virus SIVmac239. J Virol 2008; 82(8): 4154-8.
138. Girard M, Mahoney J, Wei Q, et al. Genital infection of female chimpanzees with human immunodeficiency virus type 1. AIDS Res Hum Retrov 1998; 14(15): 1357-67.
139. Doria-Rose NA, Klein RM, Daniels MG, et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J Virol 2010; 84(3): 1631-6.
140. Shingai M, Donau OK, Plishka RJ, et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J Experiment Med 2014; 211(10): 2061-74.
141. Abela IA, Berlinger L, Schanz M, et al. Cell-cell transmission enables HIV-1 to evade inhibition by potent CD4bs directed antibodies. PLoS Pathogens 2012; 8(4): e1002634.
142. Malbec M, Porrot F, Rua R, et al. Broadly neutralizing antibodies that inhibit HIV-1 cell to cell transmission. J Experiment Med 2013; 210(13): 2813-21.
143. Chen Y, Zhang J, Hwang KK, et al. Common tolerance mechanisms, but distinct cross-reactivities associated with gp41 and lipids, limit production of HIV-1 broad neutralizing antibodies 2F5 and 4E10. J Immunol 2013; 191(3): 1260-75.
144. Zhou T, Georgiev I, Wu X, et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 2010; 329(5993): 811-7.
145. Zaunders J, van Bockel D. Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Front Immunol 2013; 4: 95.
146. Jin X, Bauer DE, Tuttleton SE, et al. Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. J Experiment Med 1999; 189(6): 991-8.
147. Buchbinder SP, Mehrotra DV, Duerr A, et al. Efficacy assessment of a cell-mediated immunity HIV-1 vaccine (the Step Study): a double-blind, randomised, placebo-controlled, test-of-concept trial. Lancet 2008; 372(9653): 1881-93.
148. Gray GE, Allen M, Moodie Z, et al. Safety and efficacy of the HVTN 503/Phambili study of a clade-B-based HIV-1 vaccine in South Africa: a double-blind, randomised, placebo-controlled testof-concept phase 2b study. Lancet Infect Dis 2011; 11(7): 507-15.
149. Hildreth JE, Hampton R, Halsey NA. Antibody-dependent cellmediated cytotoxicity can protect PBMC from infection by cellassociated HIV-1. Clin Immunol 1999; 90(2): 203-12.
150. Horton RE, McLaren PJ, Fowke K, Kimani J, Ball TB. Cohorts for the study of HIV-1-exposed but uninfected individuals: benefits and limitations. J Infect Dis 2010; 202 Suppl 3: S377-81.